Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation

William W. Busse, Monica Kraft, Klaus F. Rabe, Yamo Deniz, Paul Rowe, Marcella Ruddy, Mario Castro
European Respiratory Journal 2021; DOI: 10.1183/13993003.03393-2020
William W. Busse
1UW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Kraft
2University of Arizona Health Sciences Center, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus F. Rabe
3LungenClinic Grosshansdorf (member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany
4Christian-Albrechts University (member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Kiel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yamo Deniz
5Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Rowe
6Sanofi, Bridgewater, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcella Ruddy
5Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Castro
7University of Kansas School of Medicine, Kansas City, KS, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Asthma is a complex respiratory disease that varies in severity and response to treatment. Several asthma phenotypes with unique clinical and inflammatory characteristics have been identified. Endotypes, based on distinct molecular profiles, help to further understand the heterogeneity within asthma. Type 2 inflammation, involving both the innate (type 2 innate lymphoid cell) and adaptive (T helper type 2 cells) immune systems, underpins the complex pathophysiology of chronic inflammation in asthma, as well as the presence of comorbid disease (such as chronic rhinosinusitis with nasal polyps, allergic rhinitis, and atopic dermatitis). Type 2 inflammation is characterised by upregulation of type 2 cytokines interleukin (IL)-4, IL-5, and IL-13, immunoglobulin E (IgE)-mediated release of immune mediators, and dysfunction of epithelial or epidermal barriers. Targeting these key proximal type 2 cytokines has shown efficacy in recent studies adopting a personalised approach to treatment using targeted biologics. Elevated levels of biomarkers downstream of type 2 cytokines, including fractional exhaled nitric oxide, serum IgE, and blood and sputum eosinophils, have been linked to mechanisms involved in type 2 inflammation, and have the potential to aid diagnosis, and predict and monitor response to treatment. The objective of this review is to summarise the current understanding of the biology of type 2 inflammation in asthma, examine its influence on type 2 inflammatory comorbidities, and discuss how type 2 inflammatory biomarkers can be harnessed to further personalise treatments in the age of biologic medicines.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Busse reports personal fees from GlaxoSmithKline, personal fees from Novartis, personal fees from Regeneron Pharmaceuticals, Inc., personal fees from Sanofi, during the conduct of the study;.

Conflict of interest: Dr. Kraft reports other from American Lung Association, other from AstraZeneca, other from Chiesi, other from NIH, other from Regeneron Pharmaceuticals, Inc., other from Sanofi, during the conduct of the study; other from Elsevier, outside the submitted work;.

Conflict of interest: Dr. Rabe reports personal fees and other from AstraZeneca, personal fees and other from Boehringer Ingelheim, personal fees and other from Novartis, personal fees and other from Sanofi, personal fees and other from Teva, during the conduct of the study;.

Conflict of interest: Dr. Deniz reports personal fees and other from Regeneron Pharmaceuticals, Inc., during the conduct of the study;.

Conflict of interest: Dr. Rowe reports personal fees and other from Sanofi, during the conduct of the study;.

Conflict of interest: Dr. Ruddy reports personal fees and other from Regeneron Pharmaceuticals, Inc., during the conduct of the study;.

Conflict of interest: Dr. Castro reports other from American Lung Association, personal fees and other from AstraZeneca, personal fees and other from Boehringer Ingelheim, other from Chiesi, other from NIH, other from Novartis, other from PCORI, personal fees and other from Sanofi, other from 4D pharma, other from Aviragen Therapeutics, personal fees and other from Boston Scientific, personal fees and other from Genentech, other from Nuvaira, personal fees and other from Teva, other from Therabron Therapeutics, other from Theravance Biopharma, other from Vectura, other from Vida Pharma, personal fees from Regeneron Pharmaceuticals, Inc., other from Elsevier, during the conduct of the study;.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received September 4, 2020.
  • Accepted December 21, 2020.
  • ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org
PreviousNext
Back to top
View this article with LENS
Vol 61 Issue 1 Table of Contents
European Respiratory Journal: 61 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation
William W. Busse, Monica Kraft, Klaus F. Rabe, Yamo Deniz, Paul Rowe, Marcella Ruddy, Mario Castro
European Respiratory Journal Jan 2021, 2003393; DOI: 10.1183/13993003.03393-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation
William W. Busse, Monica Kraft, Klaus F. Rabe, Yamo Deniz, Paul Rowe, Marcella Ruddy, Mario Castro
European Respiratory Journal Jan 2021, 2003393; DOI: 10.1183/13993003.03393-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Identifying and appraising outcome measures for severe asthma: a systematic review
  • Progressive pulmonary fibrosis: an expert group consensus statement
  • Cystic fibrosis transmembrane conductance regulator in COPD: A role in respiratory epithelium and beyond
Show more Review

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society